From API synthesis to finished product to last-mile distribution, the Pharco Group operates the full pharmaceutical value chain, under one corporation.
The Pharco Group is an integrated pharmaceutical group in Egypt, built over more than 6 decades. Its 13 companies cover the full pharmaceutical value chain, R&D, API manufacturing, formulation, distribution and international operations, under one corporate ownership.
Vertical integration is what separates the Pharco Group commercially. With API supply, multiple manufacturing sites, branded generic portfolios, an established CMO platform, and group-owned pharmaceutical distribution across Egypt and MENA, Pharco can move faster on market access, absorb supply-chain volatility better than independent peers, and offer partners a single point of contact for the full molecule-to-patient journey.
Pharco's own pipeline plus international research collaborations with the University of Michigan, DNDi, Chemelectiva, Presidio Pharmaceuticals and SeegPharm.
Own facilities across the group plus licensed and CMO production for multinationals including Boehringer Ingelheim, Doppelherz, GSK, Sandoz and Synthon.
350 branded generics across 12 therapeutic areas including Rx generics, OTC products, licensed Rx, licensed OTC, APIs and medical/surgical products.
Group distribution arms, Abou Kir Trading, Pharco Impex and ZIMMO, provide regional supply chain and last-mile delivery infrastructure across Egypt and the wider MENA region.
Public-sector buyers (health ministries, government institutions) and private-sector buyers (pharmacies, clinics, hospitals, distributors) across more than 70 markets.
European-standard pharmaceutical manufacturing serving regional and international markets, with EU-GMP-aligned production lines.
Egypt's flagship branded generics producer, solid, liquid, semi-solid and sterile dosage form manufacturing across multiple therapeutic areas.
Multi-dosage-form pharmaceutical manufacturing, solid, liquid and semi-solid forms.
Pharco's Saudi manufacturing plant, extending group production into the Kingdom with GCC-standard pharmaceutical lines.
Export-focused pharmaceutical manufacturing and international market development, producing LVP, SVP and cephalosporin dosage forms for Pharco's 70+ export markets.
Specialised pharmaceutical manufacturing across multiple therapeutic areas, including hormonal and complex generic dosage forms.
Quality-focused pharmaceutical manufacturing built around a safety-first operational culture, with SGC specialization and toll manufacturing under integrated GMP standards.
Est. 2022
Biogeneric and specialty pharmaceutical development and production, established 2022 to broaden Pharco's biologics and complex generics pipeline.
Active pharmaceutical ingredient (API) manufacturing, vertical integration from raw chemistry to finished product within the Pharco Group.
Est. 1993
European distribution and licensing operations, established 1993, supporting Pharco's longest-standing European market entry.
Regional pharmaceutical distribution and supply chain management, Egypt's wholesale infrastructure backbone for the Pharco Group.
Strategic partnership in Saudi Arabia, supporting market access and pharmaceutical distribution across the GCC.
Health and wellness product development, extending the group's reach into preventive care and consumer health.
US-based pharmaceutical company within the Pharco Group's international footprint, specialty pharmaceutical R&D and commercialisation.
Explore the operations, partners and reach of the Pharco Group.
